Status:
COMPLETED
Capecitabine and Bevacizumab ± Vinorelbine in Metastatic Breast Cancer
Lead Sponsor:
iOMEDICO AG
Collaborating Sponsors:
Arbeitsgemeinschaft fur Internistische Onkologie
Arbeitskreis Klinische Studien
Conditions:
Metastatic Breast Cancer
Eligibility:
FEMALE
18+ years
Phase:
PHASE3
Brief Summary
The aim of the trial is to detect the superiority of the triple combination of capecitabine, bevacizumab and vinorelbine versus the combination of capecitabine and bevacizumab in patients with metasta...
Eligibility Criteria
Inclusion
- Key
- Written informed consent.
- Able to comply with the protocol.
- ECOG Performance status 0 - 2.
- Life expectancy more than 12 weeks.
- Known ER / PR status.
- Confirmed HER2/neu-negative, adenocarcinoma of the breast with measurable or non-measurable locally recurrent or metastatic disease, who are candidates for chemotherapy.
- Previous (neo)adjuvant chemotherapy is allowed provided that the last dose of chemotherapy was applied more than 6 months prior to randomization.
- Previous adjuvant radiotherapy is allowed as part of the treatment of early breast cancer provided that no more than 30% of marrow-bearing bone was irradiated.
- No signs and symptoms of CHF.
- Adequate hepatic and renal function values.
- Adequate hematologic function values.
- Key
Exclusion
- Pregnant or lactating females.
- Previous chemotherapy for metastatic or locally recurrent breast cancer.
- Previous radiotherapy for the treatment of metastatic disease (unless given for the relief of metastatic bone pain)
- Evidence of spinal cord compression or current evidence of central nervous system (CNS) metastases.
- Major surgical procedure, open biopsy or significant traumatic in-jury within 28 days prior to randomization, or anticipation of the need for major surgery during the course of the study treatment.
- History or evidence of inherited bleeding diathesis or coagulopathy with the risk of bleeding.
- Uncontrolled hypertension (systolic \> 150 mmHg and/or diastolic \> 100 mmHg). Clinically significant (i.e. active) cardiovascular disease, requiring medication during the study and might interfere with regularity of the study treatment, or not controlled by medication.
- Non-healing wound, active peptic ulcer or bone fracture.
- History of abdominal fistula, or any grade 4 nongastrointestinal fistula, gastrointestinal perforation or intrabdominal abscess within 6 months of randomization.
- Active infection requiring i.v. antibiotics at randomization.
- Clinically significant malabsorption syndrome or inability to take oral medication.
- Known hypersensitivity to any of the study drugs or excipients.
- Concurrent treatment with any drug interfering with study medication. Concurrent participation in another clinical trial. Prior participation is allowed when the last study medication was applied more than 4 weeks prior to randomization.
Key Trial Info
Start Date :
February 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 1 2015
Estimated Enrollment :
600 Patients enrolled
Trial Details
Trial ID
NCT00868634
Start Date
February 1 2009
End Date
October 1 2015
Last Update
August 31 2016
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Onkologische Schwerpunktpraxis Eppendorf
Hamburg, Germany